Form 4: CSO Chad Cowan Sells IPSC Shares for Tax Obligations

Century Therapeutics' Chief Scientific Officer, Chad Cowan, sold 5,462 shares of common stock to cover tax withholding obligations related to RSU vesting.

Summary

• Chad Cowan, Chief Scientific Officer of Century Therapeutics, Inc. (IPSC), reported a transaction on November 20, 2025.
• He sold 5,462 shares of common stock at a price of $0.501 per share.
• The sale was automatic and not at his discretion, executed solely to cover tax withholding obligations associated with the vesting of restricted stock units.
• Following this transaction, Cowan directly owns 987,027 shares and indirectly owns 10,697 shares through the Cowan Investment Nominee Trust.

Sentiment

Score: 5

Explanation: The transaction is a routine, non-discretionary sale of shares by an insider to cover tax withholding obligations upon the vesting of restricted stock units, which is a common and expected event and does not reflect a change in management's sentiment towards the company.

Positives

• The sale was non-discretionary, solely to cover tax withholding obligations from restricted stock unit (RSU) vesting, indicating a routine compensation event rather than a discretionary sale.
• Chad Cowan retains significant direct beneficial ownership of 987,027 common shares and indirect ownership of 10,697 shares after the transaction.

Negatives

• A reduction in direct beneficial ownership by 5,462 common shares occurred due to the sale.

Future Outlook

NA

Management Comments

• "The sales reported on this Form 4 represent the number of shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. Such sales were automatic and not at the discretion of the Reporting Person."
• "The Reporting Person disclaims beneficial ownership except to the extent of any pecuniary interest therein, and this report shall not be deemed an admission that such shares are beneficially owned by him for Section 16 or any other purpose." (Regarding shares held by the Cowan Investment Nominee Trust)

Industry Context

This is a routine insider transaction for tax purposes, common across all industries for publicly traded companies when restricted stock units (RSUs) vest. It does not provide specific insights into Century Therapeutics' operational performance or broader industry trends.

Stakeholder Impact

• Shareholders: The sale represents a minor, non-discretionary reduction in insider ownership, which is a routine event and typically does not signal a change in company fundamentals.
• Employees: The transaction reflects standard compensation practices involving restricted stock units, indicating normal employee incentive programs are in effect.

Key Dates

Recommendation

This Form 4 reports a non-discretionary sale of shares by a Chief Scientific Officer solely to cover tax withholding obligations related to RSU vesting. Such transactions are routine and do not indicate a change in the insider's view of the company's prospects or fundamental value. Therefore, it does not provide a basis for altering an existing investment recommendation.

Keywords

Century Therapeutics, IPSC, Chad Cowan, Form 4, Insider Transaction, Stock Sale, Restricted Stock Units, Tax Withholding, Beneficial Ownership, Biotechnology